# Oppenheimer Downgrades Dyne Over Small DYN-101 Trial Size

By Enna Lee

Canonical URL: https://www.tokenpost.com/news/investing/43067
Published: 2026-10-28T23:35:56.000Z
Updated: 2026-10-28T23:35:56.000Z
Section: Investing

> The firm cut its rating to Perform from Outperform, saying the study's size may weaken the significance of upcoming data.

Oppenheimer lowered its rating on Dyne Therapeutics to Perform from Outperform, pointing to the size of a trial for its myotonic dystrophy type 1 candidate as a potential limit on the significance of upcoming data.

The candidate, DYN-101, is also known as zeleciment basivarsen or z-basivarsen. Oppenheimer's concern was that the small study could weaken the significance of future results.